Skip to Main Content

Author Details

Vivek Naranbhai
Massachusetts General Hospital/Harvard Medical School
2006
89
33
PMIDPaper TitleJournal TitlePublished Year
36792425Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.Clin Lung Cancer2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37390098Prognostic biomarkers for survival in mucosal melanoma.Pigment Cell Melanoma Res2023
36977187Monocyte, Lymphocyte and Neutrophil Ratios - Easy-to-Use Biomarkers for the Diagnosis of Pediatric Tuberculosis.Pediatr Infect Dis J2023
37264229HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses.Nat Immunol2023
36798349Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study.medRxiv2023
34838892Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.Radiother Oncol2022
35587156Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.Virulence2022
35381395Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.J Allergy Clin Immunol Pract2022
35835762Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity.Nat Commun2022
35605659Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.J Invest Dermatol2022
35858344Genetic variation that determines <i>TAPBP</i> expression levels associates with the course of malaria in an HLA allotype-dependent manner.Proc Natl Acad Sci U S A2022
35364034T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.Cell2022
36526723Germline variants associated with toxicity to immune checkpoint blockade.Nat Med2022
36526722IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.Nat Med2022
36121873Genome-wide association study of leprosy in Malawi and Mali.PLoS Pathog2022
36051470Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.Ther Adv Med Oncol2022
34888672Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.J Infect Dis2022
34995482mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.Cell2022
35202566T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.Cell2022
35019948Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.JAMA Dermatol2022
34895481HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Lancet Oncol2022
35018386T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals.medRxiv2022
34752147Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.J Clin Oncol2022
33264390Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing.Arch Pathol Lab Med2021
33743213Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.Cell2021
33789879Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.J Immunother Cancer2021
33619506Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.medRxiv2021
33930298Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.Cell2021
34671780Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.medRxiv2021
34265281Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.Cell2021
34025670Epigenetic Regulation of <i>BST-2</i> Expression Levels and the Effect on HIV-1 Pathogenesis.Front Immunol2021
33097667HLA tapasin independence: broader peptide repertoire and HIV control.Proc Natl Acad Sci U S A2020
30298529The eMERGE genotype set of 83,717 subjects imputed to ~40â¿¿million variants genome wide and association with the herpes zoster medical record phenotype.Genet Epidemiol2019
31357936Predicting the risk of pulmonary tuberculosis based on the neutrophil-to-lymphocyte ratio at TB screening in HIV-infected individuals.BMC Infect Dis2019
30944352Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.Sci Rep2019
29237835HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E.J Virol2018
30005017Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1.AIDS2018
29523850Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4.Nat Commun2018
29461980Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.J Clin Invest2018
29302013Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells.Science2018
28610785Chemokines additional to IFN-γ can be used to differentiate among Mycobacterium tuberculosis infection possibilities and provide evidence of an early clearance phenotype.Tuberculosis (Edinb)2017
28256545The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.Sci Rep2017
28219444A functional SNP associated with atopic dermatitis controls cell type-specific methylation of the VSTM1 gene locus.Genome Med2017
29333522Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.Pathog Immun2017
28983013Role of HIV-specific CD8<sup>+</sup> T cells in pediatric HIV cure strategies after widespread early viral escape.J Exp Med2017
28704647HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells.Cell Host Microbe2017
28695282Host genetic variation and HIV disease: from mapping to mechanism.Immunogenetics2017
26809736Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.BMC Infect Dis2016
27817866HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region.Am J Hum Genet2016
  • 1 - 50 of 89

Recommended Authors

Edouard Lhomme
University of Bordeaux, Inserm, EUCLID/F-CRIN Clinical Trials Platform
Career Start Year 2013
Number of shared co-authors 1
Louise E Hogan
University of California San Francisco
Career Start Year 2012
Number of shared co-authors 6
Yaw Bediako
University of Ghana
Career Start Year 2011
Number of shared co-authors 0
Nicolas Tchitchek
Sorbonne University INSERM
Career Start Year 2010
Number of shared co-authors 0
Vanessa A York
University of California San Francisco
Career Start Year 2008
Number of shared co-authors 8
Djeneba Dabitao
University Clinical Research Center, University of Sciences
Career Start Year 2006
Number of shared co-authors 1
Fabio Zanini
Stanford University
Career Start Year 2006
Number of shared co-authors 1
April K Randhawa
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
George B Kyei
Noguchi Memorial Institute for Medical Research, University of Ghana
Career Start Year 2004
Number of shared co-authors 0
Nadia R Roan
University of California, USA Gladstone Institutes san francisco
Career Start Year 2003
Number of shared co-authors 7
David R Boulware
University of Minnesota
Career Start Year 2003
Number of shared co-authors 2
Sheila M Keating
University of California San Francisco
Career Start Year 2002
Number of shared co-authors 5
Timothy J Henrich
University of California san francisco
Career Start Year 2002
Number of shared co-authors 11
Kayvon Modjarrad
Center for Infectious Diseases Research, Walter Reed Army Institute of Research
Career Start Year 2002
Number of shared co-authors 0
Satish K Pillai
Vitalant Research Institute, USA University of California san francisco
Career Start Year 2001
Number of shared co-authors 8
Philip J Norris
Vitalant Research Institute
Career Start Year 2001
Number of shared co-authors 7
Davey M Smith
University of California San Diego
Career Start Year 2001
Number of shared co-authors 6
Sudhir Penugonda
Northwestern University Feinberg School of Medicine
Career Start Year 2000
Number of shared co-authors 6
Maudi Killian
University of California San Francisco
Career Start Year 1999
Number of shared co-authors 3
Viviana Simon
Icahn School of Medicine at Mount Sinai
Career Start Year 1997
Number of shared co-authors 2
Mahdad Noursadeghi
University College London
Career Start Year 1992
Number of shared co-authors 1
Ligia A Pinto
Frederick National Laboratory for Cancer Research
Career Start Year 1991
Number of shared co-authors 1
Martin L Hibberd
London School of Hygiene and Tropical Medicine
Career Start Year 1989
Number of shared co-authors 2
Pablo Tebas
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1988
Number of shared co-authors 8
Ronald G Collman
University of Pennsylvania School of Medicine
Career Start Year 1988
Number of shared co-authors 3
Ian Frank
IF School of Medicine, University of Pennsylvania
Career Start Year 1987
Number of shared co-authors 9
Amalio Telenti
Vir Biotechnology Inc.
Career Start Year 1977
Number of shared co-authors 14
Joseph B Margolick
Johns Hopkins Bloomberg School of Public Health
Career Start Year 1973
Number of shared co-authors 8
Richard A Kaslow
University of Alabama at Birmingham
Career Start Year 1972
Number of shared co-authors 6
Luis J Montaner
Wistar Institute
Career Start Year 1958
Number of shared co-authors 5

Collaborators

Anthony J Iafrate
Massachusetts General Hospital
Co-authored papers 17
Mary Carrington
Frederick National Laboratory for Cancer Research, National Cancer Institute
Co-authored papers 16
Wilfredo F Garcia-Beltran
Ragon Institute of MGH
Co-authored papers 14
Marcus Altfeld
Co-authored papers 9
Bruce D Walker
Ragon Institute of Mass General
Co-authored papers 9
Julian C Knight
University of Oxford
Co-authored papers 9
Yuko Yuki
Co-authored papers 5
Steven G Deeks
University of California san francisco
Co-authored papers 4
Anna Rautanen
Co-authored papers 4
Sharon R Lewin
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Co-authored papers 3
Steven M Wolinsky
Northwestern University Feinberg School of Medicine
Co-authored papers 3
Xiaojiang Gao
Co-authored papers 3
David W Haas
Vanderbilt University Medical Center
Co-authored papers 3
Jacques Fellay
Ecole Polytechnique Federale de Lausanne
Co-authored papers 3
Ying Qi
Co-authored papers 3
Jonathan M Carlson
Co-authored papers 3
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 3
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 2
Oliver Laeyendecker
Department of Medicine Johns Hopkins Medicine. Baltimore MD 21205USA.
Co-authored papers 2
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 2
Gavin Band
Co-authored papers 2
Matti Pirinen
Co-authored papers 2
Steven J Isakoff
Massachusetts General Hospital
Co-authored papers 2
Gregory D Kirk
Johns Hopkins Bloomberg School of Public Health
Co-authored papers 2
Stephen K Anderson
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Chris C A Spencer
University of Oxford
Co-authored papers 2
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 2
Hongchuan Li
Frederick National Laboratory for Cancer Research
Co-authored papers 2
Manjinder S Sandhu
Co-authored papers 1
Zhan Su
Co-authored papers 1
Release 1.2